Limits...
A polyvalent influenza DNA vaccine applied by needle-free intradermal delivery induces cross-reactive humoral and cellular immune responses in pigs.

Borggren M, Nielsen J, Karlsson I, Dalgaard TS, Trebbien R, Williams JA, Fomsgaard A - Vaccine (2016)

Bottom Line: Both the antibody-mediated and the recall lymphocyte immune responses demonstrated high reactivity against vaccine-specific strains and cross-reactivity to vaccine-heterologous strains.The results suggest that polyvalent DNA influenza vaccination may provide a strong tool for broad protection against swine influenza strains threatening animal as well as public health.In addition, the needle-free administration technique used for this DNA vaccine will provide an easy and practical approach for the large-scale vaccination of swine.

View Article: PubMed Central - PubMed

Affiliation: Virus Research and Development Laboratory, Department of Microbiological Diagnostics and Virology, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark. Electronic address: mabo@ssi.dk.

No MeSH data available.


Related in: MedlinePlus

Influenza-specific antibody response following DNA vaccination. Pigs were vaccinated twice (arrows) i.d. with needle-free delivery with 200 μg (n = 6), 800 μg (n = 6) or 1972 μg (n = 5) DNA, or not DNA vaccinated at all (n = 5). Levels of IgG in the sera were measured by ELISA. Recombinant influenza proteins that were (a-d) homologous to the vaccine or (e-h) heterologous to the vaccine were used as the coating antigens. All serum samples were tested using a fixed 1:100 or 1:125 serum dilution. Error bars indicate the mean ± SEM, and significant differences from the no-vaccine control group are indicated by: ****: p < 0.0001; ***: p < 0.001; **: p < 0.01; *: p < 0.05.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4940207&req=5

fig0005: Influenza-specific antibody response following DNA vaccination. Pigs were vaccinated twice (arrows) i.d. with needle-free delivery with 200 μg (n = 6), 800 μg (n = 6) or 1972 μg (n = 5) DNA, or not DNA vaccinated at all (n = 5). Levels of IgG in the sera were measured by ELISA. Recombinant influenza proteins that were (a-d) homologous to the vaccine or (e-h) heterologous to the vaccine were used as the coating antigens. All serum samples were tested using a fixed 1:100 or 1:125 serum dilution. Error bars indicate the mean ± SEM, and significant differences from the no-vaccine control group are indicated by: ****: p < 0.0001; ***: p < 0.001; **: p < 0.01; *: p < 0.05.

Mentions: Antibody responses against three out of the four tested different influenza proteins, homologous to the vaccine genes, could be detected in the vaccinated pigs (Fig. 1a−d). In particular, the HA-specific antibodies were found to be present at high titers after day 28pv1, and anti-H3 antibodies were detected at day 14pv1. The antibody response levels correlated well with the applied DNA doses. In addition, antibody responses against influenza proteins not corresponding to the vaccine genes were detected (Fig. 1e−h). Antibodies against recombinant HA of both human and swine origin (Fig. 1e,f) were seen after day 28pv1 in the two pig groups receiving the highest DNA doses. A high antibody response was detected against NP originating from H1N1pdm09 in all vaccinated groups. Both vaccinated and control pigs had low levels of influenza-specific IgG against several different antigens at day 0pv1 (Fig. 1a H1pdm09, 1C N2 1968, 1E H1 2007 and 1G NPpdm09). This low level detected at day 0 gradually deceased over time in the control group, thus indicating that these antibodies represent maternally derived antibodies (MDA).


A polyvalent influenza DNA vaccine applied by needle-free intradermal delivery induces cross-reactive humoral and cellular immune responses in pigs.

Borggren M, Nielsen J, Karlsson I, Dalgaard TS, Trebbien R, Williams JA, Fomsgaard A - Vaccine (2016)

Influenza-specific antibody response following DNA vaccination. Pigs were vaccinated twice (arrows) i.d. with needle-free delivery with 200 μg (n = 6), 800 μg (n = 6) or 1972 μg (n = 5) DNA, or not DNA vaccinated at all (n = 5). Levels of IgG in the sera were measured by ELISA. Recombinant influenza proteins that were (a-d) homologous to the vaccine or (e-h) heterologous to the vaccine were used as the coating antigens. All serum samples were tested using a fixed 1:100 or 1:125 serum dilution. Error bars indicate the mean ± SEM, and significant differences from the no-vaccine control group are indicated by: ****: p < 0.0001; ***: p < 0.001; **: p < 0.01; *: p < 0.05.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4940207&req=5

fig0005: Influenza-specific antibody response following DNA vaccination. Pigs were vaccinated twice (arrows) i.d. with needle-free delivery with 200 μg (n = 6), 800 μg (n = 6) or 1972 μg (n = 5) DNA, or not DNA vaccinated at all (n = 5). Levels of IgG in the sera were measured by ELISA. Recombinant influenza proteins that were (a-d) homologous to the vaccine or (e-h) heterologous to the vaccine were used as the coating antigens. All serum samples were tested using a fixed 1:100 or 1:125 serum dilution. Error bars indicate the mean ± SEM, and significant differences from the no-vaccine control group are indicated by: ****: p < 0.0001; ***: p < 0.001; **: p < 0.01; *: p < 0.05.
Mentions: Antibody responses against three out of the four tested different influenza proteins, homologous to the vaccine genes, could be detected in the vaccinated pigs (Fig. 1a−d). In particular, the HA-specific antibodies were found to be present at high titers after day 28pv1, and anti-H3 antibodies were detected at day 14pv1. The antibody response levels correlated well with the applied DNA doses. In addition, antibody responses against influenza proteins not corresponding to the vaccine genes were detected (Fig. 1e−h). Antibodies against recombinant HA of both human and swine origin (Fig. 1e,f) were seen after day 28pv1 in the two pig groups receiving the highest DNA doses. A high antibody response was detected against NP originating from H1N1pdm09 in all vaccinated groups. Both vaccinated and control pigs had low levels of influenza-specific IgG against several different antigens at day 0pv1 (Fig. 1a H1pdm09, 1C N2 1968, 1E H1 2007 and 1G NPpdm09). This low level detected at day 0 gradually deceased over time in the control group, thus indicating that these antibodies represent maternally derived antibodies (MDA).

Bottom Line: Both the antibody-mediated and the recall lymphocyte immune responses demonstrated high reactivity against vaccine-specific strains and cross-reactivity to vaccine-heterologous strains.The results suggest that polyvalent DNA influenza vaccination may provide a strong tool for broad protection against swine influenza strains threatening animal as well as public health.In addition, the needle-free administration technique used for this DNA vaccine will provide an easy and practical approach for the large-scale vaccination of swine.

View Article: PubMed Central - PubMed

Affiliation: Virus Research and Development Laboratory, Department of Microbiological Diagnostics and Virology, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark. Electronic address: mabo@ssi.dk.

No MeSH data available.


Related in: MedlinePlus